Edit

SCYNEXIS, Inc.

http://www.scynexis.com/

Last activity: 13.07.2025

Active

Categories: AdTechBioTechDevelopmentDrugMedtech

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant fungal infections. Our lead candidate, ibrexafungerp, is a broad-spectrum IV/oral antifungal agent representing a novel therapeutic class, that is in FDA review for the treatment of vaginal yeast infection also known as vulvovaginal candidiasis (VVC) and late-stage clinical development for multiple life-threatening fungal infections in hospitalized patients.

The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization.

Followers

624

Followers

4.39K

Mentions

Location: United States, New Jersey, Jersey City

Employees: 51-200

Total raised: $11.5M

Founded date: 2000

Twitter

Investors 1

Date	Name	Website
13.07.2025	Foresite C...	foresiteca...

Funding Rounds 1

Date	Series	Amount	Investors
23.05.2012	-	$11.5M	-

Mentions in press and media 24

Date	Title	Description
09.05.2025	Biosergen Nomination Committee Proposes New Board Member with an Extensive Tracking Record in the Development, Commercialization and Out-Licensing of Anti-Infectives	Biosergen Nomination Committee Proposes New Board Member with an Extensive Tracking Record in the Development, Commercialization and Out-Licensing of Anti-Infectives Fri, May 09, 2025 15:14 CET Report this content Stockholm, Sweden – May 9,...
18.11.2024	ExeVir Announces Michael Garrett as New CEO	ExeVir Bio, a Ghent, Belgium-based biotech company developing heavy chain-only antibodies targeting highly conserved epitopes for broad protection against infectious diseases, announced the appointment of Michael Garrett as its new Chief Ex...
30.11.2022	SCYNEXIS Announces $3 Million National Institutes of Health Grant Has Been Awarded to Case Western Reserve University Researchers to Study Second Generation Fungerp (SCY-247) to Fight Drug-Resistant F...	-
30.11.2022	SCYNEXIS Announces $3 Million National Institutes of Health Grant Has Been Awarded to Case Western Reserve University Researchers to Study Second Generation Fungerp (SCY-247) to Fight Drug-Resistant F...	Researchers to study the potential of SCY-247 to fight Candida auris (C.auris), a multidrug-resistant pathogen named as an “urgent threat” by the Centers for Disease Control (CDC) and included in the “critital priority group” on the World H...
26.04.2022	SCYNEXIS Announces Closing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants	JERSEY CITY, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the closing of its previously announced underwritten public offering of common stock, pre-funded warrants and warrants. The shares and warra...
22.04.2022	SCYNEXIS Announces Pricing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants	JERSEY CITY, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the pricing of its underwritten public offering of common stock, pre-funded warrants and warrants. The shares and warrants are being sold at...
02.01.2022	The 6 most mind-blowing human health discoveries of 2021	COVID-19 research was just the tip of the iceberg for 2021 discoveries. Getty Images There were many important scientific discoveries unrelated to Covid-19 this year. Scientists have studied and developed new treatments for everything from ...
27.12.2021	The 6 most mind-blowing human health discoveries of 2021	COVID-19 research was just the tip of the iceberg for 2021 discoveries. Getty Images There were many important scientific discoveries unrelated to COVID-19 this year. Scientists have studied and developed new treatments for everything from ...
03.06.2021	SCYNEXIS, INC. SCYNEXIS : Announces FDA Approval of BREXAFEMME (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections	JERSEY CITY, N.J. - SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, announced that the U.S. Food and Drug Administration...
14.05.2021	SCYNEXIS, INC. SCYNEXIS Secures Term Loan Facility for up to $60 Million with Hercules Capital and Silicon Valley Bank	Together with SCYNEXIS’ $93M cash balance at 12/31/20, the non-dilutive capital injections from this term loan, the recent licensing payments from Hansoh Pharma, and the monetization of 2020 New Jersey NOLs further strengthen SCYNEXIS’ bala...
21.04.2020	More positive PhIII data set stage for Scynexis' vaginal yeast infection drug approval	Months after unveiling data that showed its lead experimental compound, ibrexafungerp, helped patients with vaginal yeast infections, antifungal drug developer Scynexis is one step closer to the finish line with a se...
09.04.2020	SCYNEXIS Secures $10 Million in Financing	JERSEY CITY, N.J., April 09, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the sale ...
21.06.2019	Maze interim chief Charles Homcy passes baton to Jason Coloma; William Collier tapped as CEO of Arbutus	Jason Coloma Third Rock → Four months into Maze Therapeutics’ launch, Charles Homcy is passing the startup’s reins to another Third Rock colleague. Jason Coloma, the current COO, is leaving his role at the VC firm to become...
21.05.2019	New antibiotics are urgently needed, but economics stand in the way	Achaogen’s journey from promise to penury illustrates the Herculean task the biopharma industry faces: Fulfill a growing need for antibiotics while facing economic realities that make doing so unprofitable. As is apparent from the prolifera...
23.05.2012	With hepatitis C compound in phase 2, Scynexis raises $11.5M of $15M target	Scynexis’ main business is providing services to help pharmaceutical and biotechnology companies with their drug discovery and development efforts. That work generated $18 million in 2011 revenue for the Durham, North Carolina-based company...
16.02.2012	Life sciences companies make pharma pitches, hope for hits with investors	Heat Bio. Heat’s lead drug program is an experimental lung cancer treatment in phase 2 clinical trials. Heat Bio’s proprietary technology reprograms tumor cells to pump out antigens to fight disease. CEO Jeff Wolf said that when the company...
15.02.2012	Pharmas, medical device makers set to pitch at CED Life Science conference	A total of 16 companies are scheduled to make presentations, split evenly between pharmaceuticals and medical devices. Here’s a quick rundown of the presenting companies, all of whom are either based in North Carolina’s Research Triangle or...
19.12.2011	Scynexis aims to raise $15M; hepatitis C drug candidate in phase 2 trials	Scynexis collaborates with pharmaceutical companies on their drug discovery and development efforts and it already has a long list of drug partners that include Merck (NYSE:MRK), Sanofi (NYSE:SNY) and Roche (OTC:RHHBY). In the last five yea...
10.01.2006	SCYNEXIS Europe is now Selcia following spin off from SCYNEXIS, Inc	SCYNEXIS Europe is now Selcia following spin off from SCYNEXIS, Inc 10-01-2006 Research Triangle Park, North Carolina and ONGAR, UK . .. SCYNEXIS, Inc., a medicinal chemistry-focused drug discovery and development company, has sold its whol...
-	Life sciences companies make pharma pitches, hope for hits with investors	Life sciences companies presenting at CED’s Life Science Conference largely stuck to script. Prepared remarks. PowerPoint presentations. After 11 minutes on stage, another presenter took their place. Immunotherapy company Heat Biologics bro...
-	With hepatitis C compound in phase 2, Scynexis raises $11.5M of $15M target	Drug discovery and development company Scynexis, which is in midstage clinical development of a novel hepatitis C treatment, is getting closer to reaching its $15 million fundraising target. Scynexis has raised nearly $11.5 million so far, ...
-	New antibiotics are urgently needed, but economics stand in the way	On March 10, 2017, shares of antibiotic developer Achaogen traded at $27 on the Nasdaq. Two years later, it has become a penny stock trading at around 9 cents per share after the company filed for bankruptcy under Chapter 11, on April 15, a...
-	Scynexis aims to raise $15M; hepatitis C drug candidate in phase 2 trials	Drug discovery and development firm Scynexis, which is moving forward on a new hepatitis C treatment, has raised $5 million in a fundraising effort targeted to reach up to $15 million. A total of nine investors have invested in the round th...
-	Pharmas, medical device makers set to pitch at CED Life Science conference	Life science companies and investors, let’s make a deal. The annual CED Life Science Conference kicks off in Raleigh, North Carolina today where small drug developers hope to make the right connection with a big pharmaceutical company or ve...

SCYNEXIS, Inc.

Investors 1

Funding Rounds 1

Mentions in press and media 24

Reviews 0